Homearrow Blogsarrow Chronic Kidney Disease Explained: GFR, Stages, and an Integrative Approach to Kidney Health
January 14, 2026

Chronic Kidney Disease Explained: GFR, Stages, and an Integrative Approach to Kidney Health

Chronic kidney disease often progresses silently. Understanding GFR, kidney disease stages, and integrative treatment strategies can help slow or prevent decline.

Chronic Kidney Disease Explained: GFR, Stages, and an Integrative Approach to Kidney Health

Chronic Kidney Disease: Understanding GFR, Disease Stages, and an Integrative Path to Kidney Health

Chronic kidney disease (CKD) is one of the most underrecognized yet impactful chronic health conditions worldwide. Millions of people have impaired kidney function without knowing it, largely because early disease is silent. By the time symptoms appear, significant and often irreversible damage has already occurred.

Despite this, CKD is not an inevitable march toward dialysis for most people. In many cases, progression can be slowed dramatically, and sometimes halted, when kidney stressors are identified early and addressed comprehensively.

This article explains what chronic kidney disease is, how kidney function is measured, why hypertension and blood sugar dysregulation are the primary drivers, and how an integrative medicine approach can be used to protect and optimize kidney health.

What Do the Kidneys Actually Do?

The kidneys are not just filtration organs. They are highly metabolic, vascular, and hormonally active tissues responsible for:

  • Filtering metabolic waste products

  • Regulating fluid balance

  • Maintaining electrolyte equilibrium

  • Controlling blood pressure via the renin-angiotensin-aldosterone system

  • Activating vitamin D

  • Producing erythropoietin for red blood cell production

  • Regulating acid-base balance

Each kidney contains roughly one million nephrons, the microscopic filtration units responsible for blood cleansing. Kidney disease reflects progressive nephron injury and loss, often driven by vascular and metabolic stress.

What Is Chronic Kidney Disease?

Chronic kidney disease is defined as persistent evidence of kidney damage or reduced kidney function lasting at least three months.

This can include:

  • Reduced glomerular filtration rate (GFR)

  • Protein or albumin in the urine

  • Structural abnormalities

  • Persistent abnormalities in blood markers

CKD is not a single disease. It is a spectrum of injury caused by multiple overlapping insults.

Understanding GFR: The Cornerstone of Kidney Assessment

What Is GFR?

Glomerular filtration rate (GFR) represents the volume of blood filtered by the kidneys per minute. It is the most widely used measure of overall kidney function.

A normal GFR in a healthy adult is typically above 90 mL/min/1.73m², though it declines gradually with age.

Lower GFR values reflect reduced filtering capacity and nephron loss.

How GFR Is Estimated

Directly measuring GFR is complex and impractical in routine care. Instead, GFR is estimated (eGFR) using blood biomarkers.

The two most clinically relevant markers are:

  • Creatinine

  • Cystatin C

Each provides different information.

Creatinine-Based GFR

What Is Creatinine?

Creatinine is a waste product generated from muscle metabolism. It is filtered by the kidneys and excreted in urine.

Serum creatinine levels rise as kidney function declines.

Limitations of Creatinine

Creatinine is influenced by factors unrelated to kidney health, including:

  • Muscle mass

  • Age

  • Sex

  • Physical activity

  • Protein intake

  • Certain medications

As a result, creatinine-based GFR can overestimate kidney function in people with low muscle mass and underestimate function in very muscular individuals.

Cystatin C–Based GFR

What Is Cystatin C?

Cystatin C is a small protein produced by all nucleated cells at a relatively constant rate. It is freely filtered by the kidneys and not significantly affected by muscle mass.

Advantages of Cystatin C

Cystatin C:

  • Is less influenced by muscle mass

  • Provides a more accurate estimate in older adults

  • Detects early kidney dysfunction sooner in many cases

  • Improves risk prediction for cardiovascular disease and mortality

Why Using Both Matters

The most accurate assessment of kidney function often comes from combined creatinine and cystatin C–based GFR calculations.

This approach:

  • Reduces estimation error

  • Improves early detection

  • Better predicts long-term outcomes

In integrative and preventive medicine, cystatin C is increasingly favored for nuanced risk assessment.

Stages of Chronic Kidney Disease

Chronic kidney disease is categorized into five stages based on GFR.

Stage 1: GFR ≥90 with Evidence of Kidney Damage

  • Kidney function appears normal

  • Structural or biochemical abnormalities are present

  • Often detected via urine testing

This stage is often reversible if underlying drivers are addressed.

Stage 2: GFR 60–89

  • Mild reduction in kidney function

  • Often asymptomatic

  • Common in early hypertension or insulin resistance

Intervention at this stage can dramatically slow progression.

Stage 3: GFR 30–59

Stage 3 is divided into:

  • 3a: GFR 45–59

  • 3b: GFR 30–44

This is where complications such as anemia, mineral imbalance, and cardiovascular risk increase significantly.

Stage 4: GFR 15–29

  • Severe kidney impairment

  • Metabolic complications become prominent

  • Preparation for renal replacement therapy may begin

Aggressive management is required.

Stage 5: GFR <15

  • End-stage kidney disease

  • Dialysis or transplant may be required

The goal is to prevent progression to this stage whenever possible.

The Two Most Common Drivers of Kidney Disease

1. Hypertension

High blood pressure damages the delicate blood vessels within the kidneys.

Over time:

  • Glomeruli scar

  • Filtration efficiency declines

  • Protein leaks into the urine

  • Kidney ischemia worsens

Hypertension is both a cause and consequence of kidney disease.

2. Elevated Blood Sugar and Insulin Resistance

Chronic hyperglycemia leads to:

  • Glycation of kidney tissues

  • Increased oxidative stress

  • Glomerular hyperfiltration

  • Inflammation and fibrosis

Even early insulin resistance, before overt diabetes, increases kidney risk.

An Integrative Medicine Approach to Kidney Health

Protecting kidney function requires addressing vascular health, metabolic control, inflammation, and oxidative stress simultaneously.

Lifestyle Foundations

Blood Pressure Optimization

Targets should be individualized but often include:

  • Reducing sodium intake

  • Increasing potassium-rich foods when appropriate

  • Weight normalization

  • Regular physical activity

  • Stress reduction

Blood Sugar Control

Key strategies include:

  • Low-glycemic nutrition

  • Adequate protein intake without excess

  • Time-restricted eating when appropriate

  • Improving insulin sensitivity through movement

Hydration

Chronic underhydration increases kidney workload. Hydration should be consistent and individualized, especially in later CKD stages.

Nutritional Strategies

  • Moderate protein intake, not excessive restriction

  • Emphasis on plant-forward diets

  • Reduction of ultra-processed foods

  • Limiting phosphate additives

  • Avoiding high-fructose sweeteners

Supplement Support for Kidney Health

Vascanox

Vascanox supports endothelial nitric oxide production, improving vascular function and blood flow. Because kidney health is deeply tied to microvascular integrity, supporting nitric oxide signaling can help reduce intraglomerular pressure and ischemic injury.

Arterosil

Arterosil targets the endothelial glycocalyx, a protective layer lining blood vessels. Glycocalyx degradation is common in hypertension, diabetes, and kidney disease. Supporting this structure helps improve vascular resilience and filtration dynamics.

Additional Beneficial Supplements

  • Omega-3 fatty acids: Reduce inflammation and proteinuria

  • Curcumin: Anti-inflammatory and antifibrotic effects

  • CoQ10: Supports mitochondrial function in renal tissue

  • Magnesium: Improves insulin sensitivity and blood pressure

  • N-acetylcysteine: Supports antioxidant defenses

  • Astragalus: Traditionally used for renal protection in early CKD

All supplementation should be individualized based on stage and laboratory findings.

Peptides in Kidney Health (Emerging Area)

Peptides are not primary CKD treatments but may support underlying mechanisms.

Potential areas of benefit include:

  • Endothelial repair peptides

  • Anti-inflammatory peptides

  • Mitochondrial support peptides

Clinical data is still emerging, and use should be cautious and supervised.

Medication Strategies

Blood Pressure Medications

ACE inhibitors and ARBs:

  • Reduce intraglomerular pressure

  • Lower proteinuria

  • Slow CKD progression

Glucose-Lowering Medications

SGLT2 inhibitors have demonstrated:

  • Reduced CKD progression

  • Lower cardiovascular risk

  • Improved renal outcomes independent of glucose lowering

These agents have reshaped kidney disease management.

Mineral and Bone Support

Vitamin D analogs, phosphate binders, and bicarbonate therapy may be indicated in later stages.

Monitoring and Early Detection

Regular monitoring should include:

  • GFR using creatinine and cystatin C

  • Urine albumin-to-creatinine ratio

  • Blood pressure tracking

  • Metabolic markers

  • Electrolytes and acid-base status

Early detection is the most powerful intervention.

The Bigger Picture

Chronic kidney disease is not just a renal problem. It is:

  • A vascular disease

  • A metabolic disease

  • An inflammatory disease

An integrative approach addresses all three.

Key Takeaways

  • GFR is the primary measure of kidney function

  • Creatinine and cystatin C provide complementary information

  • Hypertension and elevated blood sugar are the leading causes of CKD

  • Early stages are often reversible or stabilizable

  • Integrative strategies can meaningfully slow progression

Scientific References

  1. KDIGO Clinical Practice Guidelines for CKD Evaluation and Management

  2. Stevens LA, et al. Assessing kidney function — measured and estimated GFR. N Engl J Med.

  3. Shlipak MG, et al. Cystatin C versus creatinine in determining risk. N Engl J Med.

  4. Brenner BM, et al. Hypertension and kidney disease progression. Kidney International.

  5. Heerspink HJL, et al. SGLT2 inhibitors in chronic kidney disease. Lancet.

  6. Vaziri ND. Oxidative stress and inflammation in CKD. Semin Nephrol.